InDex Pharmaceuticals Holding AB (FLERIE) AI Stock Analysis

• Market Cap: kr3.68B
• Dividend Yield: N/A
• Average Volume (3M): 69.42K
• Price to Earnings (P/E): 0.3
• Beta (1Y): -0.11
• Revenue Growth: -75.91%
• EPS Growth: N/A
• Country: SE
• Employees: 8
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - General
• EPS (TTM): -3.21
• Shares Outstanding: 78,066,410
• 10 Day Avg. Volume: 71,696
• 30 Day Avg. Volume: 69,415
• PEG Ratio: 2.46
• Price to Book (P/B): 8.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: kr45.00 ▼(-4.05%Downside)

The overall stock score is weighted heavily by financial performance challenges, with negative profitability and cash flow issues. While technical indicators show some short-term bullishness, valuation concerns with a low P/E ratio and no dividend yield weigh down the score. The lack of earnings call insights and corporate events limits the analysis to these components.

InDex Pharmaceuticals Holding AB Business Overview & Revenue Model

Company Description

InDex Pharmaceuticals Holding AB (FLERIE) is a biopharmaceutical company based in Sweden, dedicated to the development of innovative pharmaceutical products targeting immunological diseases. The company's core focus is on its lead product candidate, cobitolimod, an anti-inflammatory drug intended for the treatment of ulcerative colitis. InDex aims to address significant unmet medical needs by advancing cobitolimod through clinical development and eventually bringing it to market.

How the Company Makes Money

InDex Pharmaceuticals generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company's key revenue stream is expected to come from the successful development, approval, and subsequent sales of cobitolimod. InDex may also enter into strategic partnerships or licensing agreements with larger pharmaceutical companies to co-develop or market cobitolimod, which could provide additional revenue in the form of upfront payments, milestones, and royalties. Additionally, the company may seek funding through public or private investments to support its research and development activities.

InDex Pharmaceuticals Holding AB Financial Statement Overview

Summary

InDex Pharmaceuticals Holding AB faces significant challenges in profitability and cash flow, typical of emerging biotechnology firms. The income statement and cash flow statement reveal operational difficulties, with negative EBIT, net income, and cash flows. However, the balance sheet reflects strong equity and low leverage, indicating financial stability.

Income Statement

The company has struggled with profitability, as evidenced by negative EBIT and net income. The gross profit margin is nonexistent with consistently negative gross profit. Revenue growth is stagnant, with minimal revenue in recent years. These factors indicate significant challenges in operational efficiency and market penetration.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, indicating financial stability. The debt-to-equity ratio is minimal, suggesting low leverage and reduced financial risk. However, asset growth has not been matched by revenue growth, which could indicate inefficiencies in asset utilization.

Cash Flow

Operating and free cash flows are persistently negative, highlighting cash flow challenges. The high financing cash flow suggests reliance on external funding, which may not be sustainable long-term. The operating cash flow to net income ratio is poor, indicating inefficiencies in converting earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	100.00K	100.00K	97.50M	0.00	0.00	35.00K
Gross Profit	-18.00M	-41.60M	93.35M	-1.07M	-1.25M	-57.73M
EBITDA	-136.60M	-225.90M	-93.82M	-99.15M	-101.66M	-56.11M
Net Income	-329.50M	-228.00M	-95.27M	-100.33M	-103.04M	-57.42M
Balance Sheet
Total Assets	3.96B	4.22B	299.39M	351.34M	445.20M	61.18M
Cash, Cash Equivalents and Short-Term Investments	802.10M	865.10M	294.27M	344.93M	428.45M	53.83M
Total Debt	800.00K	800.00K	2.30M	3.25M	1.28M	2.34M
Total Liabilities	10.80M	25.30M	60.50M	17.38M	11.16M	11.86M
Stockholders Equity	3.95B	4.20B	238.88M	333.96M	434.04M	49.33M
Cash Flow
Free Cash Flow	-1.51M	-17.00M	-37.98M	-129.44M	-124.06M	-71.56M
Operating Cash Flow	-1.51M	-17.00M	-37.98M	-129.44M	-124.06M	-70.65M
Investing Cash Flow	-65.90M	-19.80M	-625.20M	0.00	0.00	-909.00K
Financing Cash Flow	572.07M	571.90M	634.70M	-818.00K	486.39M	-1.40M

InDex Pharmaceuticals Holding AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 46.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLERIE, the sentiment is Positive. The current price of 46.9 is above the 20-day moving average (MA) of 46.12, above the 50-day MA of 43.73, and above the 200-day MA of 45.16, indicating a bullish trend. The MACD of 0.84 indicates Positive momentum. The RSI at 64.58 is Neutral, neither overbought nor oversold. The STOCH value of 75.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:FLERIE.

InDex Pharmaceuticals Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLERIE	52 Neutral	kr3.68B	0.31	-15.21%	―	-75.91%	―
HNSA	51 Neutral	kr2.28B	―		―	9.53%	41.19%
Sector *	50 Neutral	kr5.29B	11.97	-82.66%	9.67%	36.04%	27.80%
SYNACT	48 Neutral	€916.47M	―	-48.22%	―	―	67.70%
XSPRAY	47 Neutral	€1.70B	―	-42.24%	―	―	-19.44%
BINV	46 Neutral	kr2.31B	―	-45.80%	―	-0.57%	-39.92%
VICO	45 Neutral	kr1.85B	―	-40.15%	―	―	63.85%